Clinical trials: Cancer Therapy-Related Cardiac Dysfunction
Coronary Microvascular Dysfunction, Cardiotoxicity
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy.
- Conditions
- Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- NCT06332131
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy
The potential cardiovascular toxicity of tumor treatment and its resulting cardiovascular events have gradually become an important health risk for tumor survivors.
- Trial name
- ProtECtion (NCT05504148)
- Testing
- crocin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Cardiotoxicity, HER2-positive Breast Cancer
Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction
Breast cancer is the most common cancer in the United Kingdom (UK), but improvements in treatment mean 3 in 4 people survive for more than 10 years.
- Conditions
- Cardiotoxicity, HER2-positive Breast Cancer, Heart Failure, Cancer, Therapy-Related
- Trial name
- HER-SAFE (NCT05880160)
- Testing
- Phased withdrawal of heart failure medications
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
Cardiotoxicity, Heart Failure
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effects, including heart failure.
- Conditions
- Cardiotoxicity, Heart Failure, Neoplasms, Breast Neoplasms
- Trial name
- ML-CardioTox (NCT07191730)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Caen
Breast Cancer, Cardiac Dysfunction
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
The purpose of this study is to find out if adding vericiguat to standard treatment for cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment alone.
- Trial name
- NCT05806138
- Testing
- Vericiguat, Optimal medical therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Heart Failure, Cancer, Therapy-Related
Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study
Therapeutic advances have significantly improved the survival of patients with cancer. However, these novel therapies are associated with a concomitant increase in the prevalence of toxicity, including cardiovascular…
- Trial name
- NCT06268535
- Testing
- Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023
- Where
- France
- Volunteers
- 36,580,288 people
- Sponsor
- University Hospital, Caen
Heart Failure, Heart Dysfunction
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
- Trial name
- TREAT-HF (NCT05194111)
- Testing
- Sacubitril-valsartan, Valsartan, Carvedilol
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Virginia Commonwealth University
Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management…
- Conditions
- Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology, Cancer Survivorship, Cardiovascular Risk
- Trial name
- CORE-CTRCD (NCT07622394)
- Testing
- Structured Cardio-Oncology Rehabilitation, Usual Care
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Xinjiang Medical University
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Chemotherapeutic Toxicity, Cardiotoxicity
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical…
- Conditions
- Chemotherapeutic Toxicity, Cardiotoxicity, Heart Failure, Breast Cancer
- Trial name
- NCT05892146
- Testing
- Prevention therapy, Rescue therapy
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Cheng-Kung University Hospital
Cancer Therapy-Related Cardiac Dysfunction, Heart Failure
Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography
This study investigates the use of AI-enhanced electrocardiogram (ECG) for risk stratification of cancer therapy-related cardiac dysfunction (CTRCD) before the initiation of cancer therapy.
- Conditions
- Cancer Therapy-Related Cardiac Dysfunction, Heart Failure, Left Ventricular Dysfunction
- Trial name
- NCT07515859
- Testing
- No intervention (retrospective observational study)
- Where
- South Korea
- Volunteers
- 31,486 people
- Sponsor
- Yonsei University
Malignancies, Cardiovascular Diseases
Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
Little is known about cancer therapy-related cardiac dysfunction occuring in children treated by anticancer drugs for malignancies.
- Conditions
- Malignancies, Cardiovascular Diseases, Children, Only
- Trial name
- NCT05602103
- Testing
- use of anticancer drugs in monotherapy or in combination therapy
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Caen
Breast Cancer, Left Ventricular Dysfunction
Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity
Breast cancer is the leading cause of cancer among Canadian women with nearly 26,000 new cases diagnosed each year. Fortunately, advancements in diagnostic tools and curative treatments have significantly improved overall…
- Conditions
- Breast Cancer, Left Ventricular Dysfunction, Heart Failure, Systolic
- Trial name
- CORE (NCT03089502)
- Testing
- Exercise Rehabilitation
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, Heart Disease
STOP Heart Disease in Breast Cancer Survivors Trial
The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on changes to the heart among women undergoing breast cancer treatment.
- Conditions
- Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
- Trial name
- STOP (NCT02674204)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Cancer Therapy-Related Cardiac Dysfunction
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with…
- Trial name
- CARPTOX-BC (NCT06881940)
- Testing
- Rehabilitation Program, No Rehabilitation Program
- Where
- 2 sites in Mexico
- Volunteers
- 284 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER
Non-ischemic Cardiomyopathy, Cardiomyopathies
Cardiovascular Multimodality Imaging Study
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis.
- Conditions
- Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy
- Trial name
- NCT06610019
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Montefiore Medical Center
Insufficiency;Cardiac, Cancer
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
New therapies for cancer increased patient survival, but led to the recognition of adverse effects associated with cancer treatment, such as the use of chemotherapy.
- Conditions
- Insufficiency;Cardiac, Cancer, Cardiotoxicity, Heart Failure
- Trial name
- NCT04047901
- Testing
- exercise training
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo General Hospital
Breast Cancer, Metastatic Breast Cancer
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity
- Trial name
- NARNIA (NCT05732051)
- Testing
- Nicotinamide Riboside
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus